DalCor To Develop Failed Roche CETP Inhibitor In Genetic Subgroup

22 Apr 2016

• By Lubna Ahmed

DalCor Pharmaceuticals has raised $150m via a private financing in order to pick up development of ex-Roche CETP inhibitor dalcetrapib for a genetically distinct group of acute coronary syndromes (ACS) patients.

DalCor To Develop Failed Roche CETP Inhibitor In Genetic Subgroup

More from Clinical Trials

More from R&D